1CP
AZN icon

17 Capital Partners’s AstraZeneca AZN Stock Holding History

17 Capital Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$281K Buy
1,427
+151
+12% +$29.1K 0.14% 156
2025
Q4 		$235K Sell
1,276
-29
-2% -$5.09K 0.12% 152
2025
Q3 		$200K Buy
+1,305
New +$198K 0.11% 144

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

17 Capital Partners's AZN Position: Q1 2026 in Review

17 Capital Partners increased its AstraZeneca (AZN) stake by 12% in Q1 2026, buying an estimated $29.1K and bringing the position to 1,427 shares worth $281K. The position accounts for 0.14% of the portfolio, ranked #156.

17 Capital Partners first reported a position in AZN in Q3 2025 and has held it in 3 quarters since. 1,379 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • 17 Capital Partners held 1,427 shares of AstraZeneca worth $281K as of Q1 2026.
  • 17 Capital Partners bought 151 AstraZeneca shares in Q1 2026, an estimated $29.1K.
  • AstraZeneca made up 0.14% of 17 Capital Partners's portfolio in Q1 2026, its #156 holding.
  • 17 Capital Partners first reported a position in AstraZeneca in Q3 2025 and has held it in 3 quarters since.
  • 1,379 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on 17 Capital Partners's 13F filing for Q1 2026, filed 13 May 2026.